Storia in 2 fonti

Novo Nordisk CEO Hints Semaglutide Could Be More Than Weight-Loss Drug - Novo Nordisk (NYSE:NVO)

Novo Nordisk exploring additional uses for obesity drug semaglutide, including potential for longevity and aesthetics.

Raccontata da

Confronto fonti

2 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo1 mese fa

Novo Nordisk exploring additional uses for obesity drug semaglutide, including potential for longevity and aesthetics.

Novo itself is beginning to generate data suggesting semaglutide may actually affect biological processes linked to aging, not just body weight.